Related references
Note: Only part of the references are listed.Mechanism of Diastolic Stiffening of the Failing Myocardium and Its Prevention by Angiotensin Receptor and Calcium Channel Blockers
Xian Wu Cheng et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2009)
Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment
Xian Wu Cheng et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II-Induced cardiovascular remodeling and renal insufficiency
Shusuke Yagi et al.
CIRCULATION RESEARCH (2008)
Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease
Shigeru Shibata et al.
NATURE MEDICINE (2008)
Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction
Carola Doerries et al.
CIRCULATION RESEARCH (2007)
Podocyte as the target for aldosterone - Roles of oxidative stress and Sgk1
Shigeru Shibata et al.
HYPERTENSION (2007)
Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure
Xian Wu Cheng et al.
HYPERTENSION (2006)
Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker
Miki Nagase et al.
HYPERTENSION (2006)
Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure
Masako Saka et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2006)
Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats
K Nagata et al.
HYPERTENSION (2006)
Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure
S Ichihara et al.
CARDIOVASCULAR RESEARCH (2006)
Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease
T Nakamura et al.
AMERICAN JOURNAL OF NEPHROLOGY (2006)
Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells
IZ Jaffe et al.
CIRCULATION RESEARCH (2005)
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
AS Go et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells
RA Markle et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)
Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy
K Node et al.
CIRCULATION (2003)
Nephrin expression is reduced in human diabetic nephropathy - Evidence for a distinct role for glycated albumin and angiotensin II
S Doublier et al.
DIABETES (2003)
Pitavastatin-induced Thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family
K Masamura et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress
S Delbosc et al.
HYPERTENSION (2002)
Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor
D Le Menuet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.
A Chrysostomou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Monocyte chemoattractant protein-1 is upregulated in rats with volume-overload congestive heart failure
TM Behr et al.
CIRCULATION (2000)
Share Paper
